[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336826-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336826-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-activation-of-the-notch-signaling-pathway-by-ube2c-promotes-the-proliferation-and-metastasis-of-hepatocellular-carcinoma","The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma","","UBE2C, a ubiquitin-conjugating enzyme, acts as an oncogene in multiple human cancers, but its specific effect on hepatocellular carcinoma (HCC) remained uncertain. Using TCGA analyses and clinical specimens, elevated UBE2C expression correlated with unfavorable prognosis. Functional studies showed UBE2C enhanced HCC growth and metastatic behavior. Mechanistically, UBE2C activated Notch signaling through increased N1ICD and Hes1 and RBP-JK luciferase reporter activation; DAPT abolished UBE2C’s oncogenic effects, and N1ICD overexpression mitigated UBE2C knockdown.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-activation-of-the-notch-signaling-pathway-by-ube2c-promotes-the-proliferation-and-metastasis-of-hepatocellular-carcinoma/336826/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-activation-of-the-notch-signaling-pathway-by-ube2c-promotes-the-proliferation-and-metastasis-of-hepatocellular-carcinoma/336826.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does UBE2C affect hepatocellular carcinoma progression?","Question",{"text":63,"@type":64},"UBE2C is elevated in HCC and is associated with an unfavorable prognosis. Its activity promotes HCC proliferation and metastasis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence links UBE2C to Notch pathway activation?",{"text":68,"@type":64},"UBE2C increases Notch pathway components N1ICD and Hes1 and activates the RBP-JK luciferase reporter. Notch pathway inhibition with DAPT eliminates UBE2C’s oncogenic role.",{"name":70,"@type":61,"acceptedAnswer":71},"Which experimental strategy supports the causal role of Notch signaling?",{"text":72,"@type":64},"Rescue experiments show that DAPT treatment removes the oncogenic effects of UBE2C, while N1ICD overexpression alleviates the anti-carcinogenic impact of UBE2C knockdown.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336826,1790192769,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma  \nPing Zhan1,4, Yuyan Lu1,4, Jing Lu1, Yizhe Cheng1, Changhong Luo1, Fan Yang1, Wenqing Xi2, Jinzhu Wang2,3, Xuesong Cen1, Fuqiang Wang2􀀍, Chengrong Xie1􀀍 & Zhenyu Yin2􀀍  \nUBE2C, a ubiquitin-conjugating enzyme, functions as an oncogene in different types of human cancers. Nonetheless, the exact influence of UBE2C on the development of HCC via regulation of ubiquitination remains uncertain. Here, we found that UBE2C displayed elevated levels of expression in HCC and was associated with an unfavorable prognosis, as evidenced by the analysis of theTCGA database and the examination of clinical specimens. The role of UBE2C in HCC revealed its ability to promote the growth and metastasis of HCC. Mechanistically, UBE2C activated Notch signaling, as evidenced by the upregulation of N1ICD and Hes1, crucial components of the Notch pathway, and activation of the RBP-JK luciferase reporter by UBE2C. Finally, rescue experiments demonstrated that the oncogenic role of UBE2C was eliminated through treatment with the Notch inhibitor DAPT, while overexpression of N1ICD alleviated the anticarcinogenic impact of knockdown of UBE2C. Altogether, the results of our study indicate that UBE2C plays a role in the activation of Notch signaling and could potentially serve as a viable target for therapeutic interventions in HCC.  \nKeywords EMT, Ubiquitination, Notch signaling  \nWith limited treatment choices and a rising death rate, hepatocellular carcinoma (HCC) has emerged asa significant global cancer1. Chronic viral hepatitis, specifically hepatitis B and hepatitis C, along with nonalcoholic steatohepatitis (NASH) and excessive alcohol consumption, play significant roles in the development of hepatocarcinogenesis. The incidence and mortality rates of HCC are surpassing those of other malignancies in the United States, underscoring the urgent need for effective medical interventions. Despite the availability of treatments such as liver resection, transplantation, and ablation for early detected tumors, HCC remains an aggressive, invasive malignancy that poses challenges in early diagnosis, resulting in limited treatment options and poor survival rates2,3. Therefore, better understanding of HCC development and progression is urgently needed.  \nProtein ubiquitination entails the covalent attachment of numerous ubiquitin molecules to the protein substrate, subsequently leading to degradation by the 26 S proteasome complex. This intricate process relies on the concerted activity of three distinct enzymes: ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3)4,5. UBE2C functions as a ubiquitin-conjugating enzyme and works together with the anaphase-promoting complex/cyclosome (APC/C) to control the advancement of the cell cycle, guaranteeing a smooth shift from metaphase to anaphase6,7. Its gene, UBE2C, resides within the 20q13.1 locus, a domain renowned for its amplification in a diverse array of malignancies, including the gastro-esophageal carcinomas8. Notably, overexpression of UBE2C has been discerned in neoplastic tissues of various histological  \n1Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, School of Medicine, Zhongshan Hospital of Xiamen University, Xiamen University, 209 South Hubin Road, Xiamen 361004, Fujian Province, China. 2Department of Hepatobiliary Surgery, Xiamen Key Laboratory of Liver Diseases, Xiamen Hospital of Traditional Chinese Medicine, Beijing University of Chinese Medicine, 1739 Xianyue Road, Xiamen 361001, Fujian Province, China. 3College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian Province, China. 4Ping Zhan and Yuyan Lu contri","cbCaijertp0XyJ8h","https://ap.wps.com/l/cbCaijertp0XyJ8h","pdf",10355122,15,"English","# Overview\n## UBE2C in HCC and clinical relevance\n## UBE2C mechanisms via ubiquitination\n## Notch pathway activation and downstream genes","[{\"question\":\"How does UBE2C affect hepatocellular carcinoma progression?\",\"answer\":\"UBE2C is elevated in HCC and is associated with an unfavorable prognosis. Its activity promotes HCC proliferation and metastasis.\"},{\"question\":\"What evidence links UBE2C to Notch pathway activation?\",\"answer\":\"UBE2C increases Notch pathway components N1ICD and Hes1 and activates the RBP-JK luciferase reporter. Notch pathway inhibition with DAPT eliminates UBE2C’s oncogenic role.\"},{\"question\":\"Which experimental strategy supports the causal role of Notch signaling?\",\"answer\":\"Rescue experiments show that DAPT treatment removes the oncogenic effects of UBE2C, while N1ICD overexpression alleviates the anti-carcinogenic impact of UBE2C knockdown.\"}]","The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma | PDF",1790016755,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/970f746577167feea52625a796b9b622.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b55889aaa2cb766da687b6173aa757a7.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47a8a6ef1a093a7dcfb593d867ce85ba.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94ef29e8604e947b55654de1bb02afd1.webp",980,1287]